CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ReNerve Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ReNerve Ltd
157 Heidelberg Road, Northcote
VIC  3070  Australia Ticker: RNVRNV

Business Summary
ReNerve Limited is an Australia-based biotechnology company engaged in advanced nerve repair and regeneration solutions. The Company is focused on commercializing medical devices and tissue engineering products that address significant unmet needs in peripheral nerve damage patients. It is also developing tissue-based products for peripheral nerve repair and replacement and other related soft tissue surgical procedures. It is focused on developing products that accelerate tissue regeneration while preventing scarring and negative inflammatory responses. Its products include NervAlign Nerve Cuff, NervAlign Nerve Graft and NervAlign Bionic Nerve. NervAlign Nerve Cuff is a soft, tissue compatible protective wrap used to protect repaired injured nerves. It consists of a pliable scaffolding material that can be wrapped around the nerve, protecting surgical repairs and conforming to the nerve’s final shape, allowing regeneration to occur.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/20246/30/2024Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Reginald S.Cooper 9/16/2016 9/16/2016
Chief Executive Officer, Executive Director Julian J.Chick 9/16/2016 9/16/2016
Chief Financial Officer, Company Secretary DavidLilja
Chief Scientific Officer, Executive Director David I.Rhodes 9/16/2016 9/16/2016
Independent Non-Executive Director MichaelPanaccio 4/27/2018 4/27/2018

General Information
Outstanding Shares: 141,837,806 (As of 12/31/2024)
Stock Exchange: ASX


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, May 23, 2025